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ABSTRACT
C
onventional gene therapy has focused largely on gene
replacement in target cells. However, progress from
basic research to the clinic has been slow for reasons
relating principally to the challenges of heterologous DNA
delivery and regulation in vivo. Alternative approaches
targeting RNA have the potential to circumvent some of these
difﬁculties,particularlyastheactivetherapeuticmoleculesare
usually short oligonucleotides and the target gene transcript is
under endogenous regulation. RNA-based strategies offer a
series of novel therapeutic applications, including altered
processingofthetargetpre-mRNAtranscript,reprogramming
of genetic defects through mRNA repair, and the targeted
silencing of allele- or isoform-speciﬁc gene transcripts. This
review examines the potential of RNA therapeutics, focusing
on antisense oligonucleotide modiﬁcation of pre-mRNA
splicing, methods for pre-mRNA trans-splicing, and the
isoform- and allele-speciﬁc applications of RNA interference.
Introduction
RNA targeting is emerging as a powerful alternative to
conventional gene replacement therapies for the treatment of
genetic disorders. Although an emerging ﬁeld, RNA
modiﬁcation has the potential to circumvent some of the
shortcomings of standard gene therapy methods, including: (i)
low efﬁciency of gene transfer; (ii) limitations on transgene
size, speciﬁcally an inability to deliver genomic size loci; (iii)
insertionalmutagenesisandintegration-associatedevents;and
(iv) immune responses and toxicity due to vectors. Moreover,
some disease situations could be more amenable to correction
by RNAtargeting, such as autosomal dominant diseases,where
introduction of a functional gene does not address expression
of the dominant mutant transcript. Similarly, in disorders of
RNAprocessing,suchasaberrantsplicing,itmaybepreferable
to repair the endogenous splicing pattern, which could also
correct multiple alternative isoforms. More importantly, RNA
targeting has unique potential for therapeutic modiﬁcation of
native mRNA transcripts within a normal regulatory
environment. The potential of such approaches ranges from
elimination of the mRNA in question to modiﬁcation of the
mature mRNA product by the removal or addition of natural
elementsorexons and torepair of the mRNAtranscript by the
addition of foreign mRNA elements to create a chimeric gene
product. Many of the effector molecules underpinning these
novel methods have their origins in natural biochemical
pathways that have been discovered in recent years.
Antisense Oligonucleotide-Based Manipulation of
Pre-mRNA Splicing
Traditionally, antisense oligonucleotides (AOs) have been
employed to down-regulate gene transcription, through
either RNase-H mediated degradation or steric blockage of
gene promoter elements. More recently however, the
potential of using AOs to alter pre-mRNA processing is being
realised. Through utilisation of AO chemistries that do not
induce transcript degradation, targeted blockage of motifs
involved in splicing allows the manipulation of this process.
Given that in the Human Gene Mutation Database (http://
www.hgmd.cf.ac.uk/ac/index.php) ;10% of annotated
mutations impinge on splice sites [1], there is the potential
for this approach to be applied to diseases caused by aberrant
splicing, or where alteration of normal splicing would
abrogate the disease-causing mutation. This could include: (i)
blockage of cryptic splice sites, (ii) exon removal or inclusion
to alter isoform expression, and (iii) removal of exons to
either eliminate a nonsense mutation or restore the reading
frame around a genomic deletion.
Blockage of cryptic splicing. The concept of using AOs to
alter pre-mRNA splicing was ﬁrst demonstrated in b-
thalassemia, which is caused by mutations in the human b-
globin gene [2]. The most prevalent disease-causing
mutations disrupt splicing of introns 1 and 2 of the b-globin
pre-mRNA transcript through activation of cryptic splice
sites, preventing production and translation of the correct
mRNA [3]. Blockage of these cryptic splice sites with AOs in
erythroid cells abrogates their use, restoring normal globin
expression [4] (Figure 1A). Similarly, in Hutchinson-Gilford
progeria syndrome, a point mutation in exon 11 of the lamin
A/C (LMNA) gene causes a silent substitution (GGCﬁGGT)
that results in activation of a cryptic donor splice site [5].
Splicing between this cryptic splice site and the acceptor
splice site gives rise to a truncated LMNA mRNA containing a
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[5]. Targeting of the Hutchinson-Gilford progeria syndrome
mutation region with a 25-mer morpholino AO sterically
blocks the activated cryptic splice site, resulting in .90%
reduction in the mutant lamin at both RNA and protein level
in Hutchinson-Gilford progeria syndrome–derived
ﬁbroblasts in vitro [6].
Exon exclusion. The demonstration that AOs could block
the utilisation of cryptic splice sites led to the idea that
modiﬁcation of constitutive splicing could remodel disease-
associated pre-mRNA transcripts. In Duchenne muscular
dystrophy (DMD), nonsense or deletion mutations in the
dystrophin gene disrupt translation of a functional
dystrophin protein [7]. A less severe allelic form of the
disease, Becker muscular dystrophy, has in-frame deleted
transcripts that allow the synthesis of a shorter yet partially
functional dystrophin protein [8]. Potentially, blockage of
consensus splice sites or exon splicing enhancers (ESEs) by
modiﬁed AOs to exclude exons, could be used to partially
correct the disease by converting DMD-causing dystrophin
doi:10.1371/journal.pgen.0030109.g001
Figure 1. AO-Based Manipulation of Pre-mRNA Splicing
(A) Blockage of cryptic splicing as a therapy for b-thalassemia. Mutations within intron 2 of the b-globin gene induce usage of cryptic splice sites that
incorporate intronic sequence into the mature mRNA. Disruption of the reading frame introduces a stop codon that results in truncated b-globin
protein. Blockage of the cryptic 59 splice site with AO (blue bar) restores normal splicing pattern and functional b-globin protein is produced.
(B) Restoration of dystrophin production in the mouse model of DMD by exon exclusion. A CﬁT mutation in exon 23 of the mouse dystrophin gene
introduces a stop codon that produces a truncated nonfunctional protein. Blockage of the 59 splice site of exon 23 disrupts its recognition by splicing
machinery, resulting in removal of the in-frame exon from the dystrophin transcript. This facilitates translation of near full-length, semi-functional
dystrophin protein.
(C) Exon inclusion to increase production of SMN protein as a therapy for SMA. A silent mutation in the SMN2 gene disrupts an ESE site in exon 7,
preventing binding of the SF2/ASF splicing factor and affecting exon recognition such that the majority of SMN2 transcripts lack exon 7, producing a
poorly functional SMN protein. Targeting with a bifunctional AO (blue bar) containing a functional ESE sequence recruits the SF2/ASF factor, promoting
exon recognition and incorporation into the mature transcript, resulting in translation of normal SMN protein.
PLoS Genetics | www.plosgenetics.org June 2007 | Volume 3 | Issue 6 | e109 0846transcripts to the milder Becker-like transcripts. In the Dmd
mouse model, a nonsense mutation in exon 23 induces a
premature termination in translation. Removal of this in-
frame exon by targeting of AOs to the 59 donor splice site of
intron 23 facilitates the synthesis of a near full-length Becker
muscular dystrophy–like protein that localises correctly to
the sarcolemmal membrane [9] (Figure 1B). Systemic
intravenous administration of 29-O-methyl phosphorothioate
AOs with the copolymer F127 demonstrates low levels of
dystrophin positive ﬁbres in multiple muscle groups with
increased expression observed following repeat injections
[10]. This was further improved using morpholino AO
chemistry, with both increased dystrophin expression [11,12]
and functional improvement, as evident by increased muscle
maximum isometric tetanic force and a reduction in creatine
kinase levels [11]. This AO-based approach has also been
applied to human in vitro models of DMD, where targeted
removal of single or multiple exons has been used to restore
the reading frame around genomic deletions in DMD
patient–derived myotube cultures, such that a near full-
length dystrophin protein was induced [13,14]. The success of
these experiments, and the demonstration of dystrophin
transcript correction in human DMD muscle explants [15],
suggests great promise for this approach as a therapy for
DMD, with Phase I clinical trials recently underway.
In the microtubule-associated protein tau (MAPT) gene,
alternative splicing in exons 2, 3, and 10 of the MAPT pre-
mRNA results in expression of six isoforms in the brain [16].
Exon 10 splicing is regulated by multiple cis-acting elements
such that exclusion or inclusion gives rise to tau isoforms with
three (tau3R) or four (tau4R) microtubule binding repeats,
respectively [17]. In adult brain, these isoforms are expressed
in equal amounts, but in patients with frontotemporal
dementia with parkinsonism linked to Chromosome 17,
mutations in the MAPT gene affects exon 10 retention such
that a 2–6-fold excess of tau4R over tau3R occurs [18,19]. This
in turn is thought to affect microtubule properties, as tau4R
and tau3R have different qualitative and quantitative effects
on microtubule dynamics. Conventional MAPT cDNA
replacement to address this isoform imbalance is complicated
by the toxicity of tau overexpression [20]. To demonstrate the
potential of exon inclusion as a treatment for frontotemporal
dementia with parkinsonism linked to chromosome 17, AOs
were directed against the splice junctions of exon 10 of MAPT
pre-mRNA to efﬁciently induce its exclusion in an in vitro
system [21].
Exon inclusion. Just as targeted blockage of consensus
splice sites and ESEs promotes exon exclusion, the blockage
of exonic or intronic splicing silencers, or the introduction of
splicing enhancer sequences, can enhance exon inclusion [1].
This offers the potential to enhance expression of
alternatively spliced ‘‘weak’’ exons to induce the most
functionally preferable isoform. In spinal muscular atrophy
(SMA), mutations in the survival motor neuron (SMN1) gene
are responsible for a degenerative disease that presents as
childhood muscle weakness and, in the more serious forms,
can cause fatal respiratory failure [22]. The severity of the
disease is modiﬁed by the production of SMN protein
encoded by the paralogous gene, SMN2 [23]. Although SMN2
is nearly identical to SMN1, a silent CﬁT mutation in exon 7
abrogates an ESE site [24], weakening recognition of the
upstream 39 splice site [25] and resulting in the majority of
SMN2 transcripts lacking exon 7. As this SMND7 isoform is
unstable, and at best, only partially functional [26], the level
of full-length SMN protein is an important modiﬁer of
patient disease severity. A number of AO-based strategies
have been developed to promote exon 7 inclusion in the
SMN2 transcript. The concept of competition between the 59
splice site of exon 6 and the 39 splice sites of exons 7 and 8 led
to the notion that blockage of the exon 8 acceptor splice site
would promote splicing between exon 6 and 7 [25].
Transfection of 29-O-methyl phosphorothioate AOs [25] and
modiﬁed U7 small nuclear RNA [27] to target the intron 7/
exon 8 junction results in increased exon 7 inclusion in SMN2
transcripts and a subsequent increase in full-length SMN
protein. Manipulation of exon 7 inclusion was also
demonstrated through AO-mediated blockage of intronic
splicing silencers within intron 6 [28] and immediately
upstream of the 59 splice site of exon 7, with increased SMN
protein levels demonstrated in SMA patient derived cells [29].
Oligonucleotides were also designed to artiﬁcially introduce
splicing elements so as to promote inclusion of a target exon.
These AOs consist of two parts; an antisense sequence that
targets to the speciﬁc exon, and a noncomplementary tail
with RNA sequences that correspond to ESE sequences that
are recognised by splicing proteins. Transfection of these
AOs into SMA patient ﬁbroblasts increases the level of
endogenous SMN2 containing exon 7 from ;60% to ;85%,
the level observed in normal individuals [30] (Figure 1C).
Bifunctional AOs have also been designed with a target-
speciﬁc antisense moiety coupled to a peptide domain
designed to mimic the splicing activation domains of serine/
arginine–rich proteins. The ability of these oligonucleotides
to stimulate exon 7 inclusion was demonstrated in cell-free
splicing assays [31] and also in SMA type I ﬁbroblasts, with an
increase in SMN protein levels observed [32].
As well as restoring protein function through inclusion of
an exon essential for function, it is possible to bias natural
alternative splicing for the desired outcome. Apoptosis is a
highly regulated process, with the relative expression levels of
pro- and anti-apoptotic genes thought to be particularly
important. Deregulation of this process is one of the
hallmarks of the development and maintenance of cancer,
and is often due to splicing defects in these regulatory genes.
The bcl-x gene (also known as BCL2L1) has two splicing
variants, the pro-apoptotic bcl-xS and the anti-apoptotic bcl-
xL, which is overexpressed in various cancers [33]. Blocking of
the alternative 59 splice site in intron 2 of bcl-x with AOs shifts
splicing from the bcl-xL to the bcl-xS isoform, with a
subsequent increase in apoptotic markers in cancer cell lines
[34]. Efﬁciency of this process is improved further when this
splice site is targeted with a bifunctional AO consisting of an
antisense moiety coupled to a heterogeneous nuclear
ribonucleoprotein A1 exon silencing motif [35].
Modiﬁed AOs are a powerful tool for manipulating
alternative splicing and addressing disease-causing splicing
defects; however, there are limitations to the use of this
approach. Exon exclusion can only be applied when the
induced in-frame deletion lies in a region that is noncritical
for function. In the majority of genes, a deletion in the mRNA
transcript will disrupt protein function, rendering this
approach unsuitable. Re-administration of AOs would also be
a necessity, as these compounds have a limited biological half-
life and only transiently target the gene transcript and not
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vectors were constructed to stably express modiﬁed small
nuclear RNAs containing antisense sequences against the Dmd
mouse mutation [36]. Interarterial perfusion in the lower
limb of the Dmd mouse resulted in more than 80% expression
of dystrophin-positive ﬁbres and coincided with functional
improvement [36]. However, host immune responses to viral
proteins would limit the repeat administration, which may be
necessary, as muscles undergo cycles of degeneration and
regeneration. Similarly, viral vectors have been designed to
express bifunctional oligonucleotides containing potent
exonic enhancers to promote exon 7 inclusion in the SMN2
gene for treatment of SMA [37]. The potential off-target
effects of application of AOs in vivo have not been well
studied and remain an important issue for consideration.
Although statistically the chances of binding of a typical 25-
base oligomer to a nonspeciﬁc gene target are low, this
potentially increases when targeting common splicing motifs
or when the antisense binding region size is decreased, as is
the case for many bifunctional oligonucleotides. There is also
the consideration of toxicity due to the AO chemistry
employed or its associated carrier, which would need to be
carefully monitored in animal models before application in
human clinical trials.
RNA Trans-Splicing
Rather than modify pre-mRNA splicing, the emergence of
RNA trans-splicing has allowed methods to be developed for
repairing genetic defects in the mature mRNA transcript.
Trans-splicing is a natural process, although rare in mammals,
which involves splicing between two separately transcribed
mRNAs such that a composite transcript is produced.
Manipulation of this process offers the potential for
induction of isoform switching or the correction of dominant
mutations by conversion to a wild type gene product. The
most common methodologies in current use are spliceosome
mediated RNA trans-splicing (SMaRT; Intronn proprietary
technology, http://www.intronn.com) and ribozyme mediated
trans-splicing.
SMaRT. In this approach, an engineered pre-mRNA trans-
splicing molecule (PTM) binds speciﬁcally to target pre-
mRNA in the nucleus such that it triggers trans-splicing in a
process mediated by the spliceosome [38]. The major
components of the PTM are a binding domain, a splicing
domain, and a coding domain. The binding domain confers
target speciﬁcity, whereas the splicing domain contains
motifs necessary for the trans-splicing reaction to occur. The
coding domain carries the portion of the wild-type cDNA,
usually one or more exons, that are necessary to repair the
targeted mutation. This repair is typically achieved by exon
replacement and subsequent removal of the defective portion
of the target pre-mRNA so that a functional gene product can
be transcribed (Figure 2A). Functional correction using
spliceosome-mediated trans-splicing has been reported in
several preclinical disease models, including cystic ﬁbrosis
(CF) [39], haemophilia A [40], and X-linked
immunodeﬁciency [41].
One of the hurdles in gene therapy for CF is the necessity
of regulating cystic ﬁbrosis transmembrane conductance
regulator (CFTR) gene expression in the appropriate cell
types in the airway. Studies of overexpression of CFTR have
suggested that it may actually be deleterious to airway cells, so
a strategy of ubiquitous expression of recombinant CFTR may
not be ideal [42]. However, as the products of trans-splicing
are dependent on cellular machinery for their expression,
localisation to the correct cell subset would be expected. The
potential of SMaRT trans-splicing has been shown in vitro and
in vivo in a DF508 model of CF, the most prevalent disease-
causing mutation [39]. Adenoviral vectors carrying a PTM
engineered to bind to intron 9 of the CFTR pre-mRNA and
trans-splice exons 10–24 of wild-type CFTR were transfected
into either human CF airway epithelial cultures or in
bronchial xenografts, resulting in functional correction of
chloride transport of 16%–22% [39]. Adenoviral vectors are
unlikely to be clinically applicable in this context, however,
due to their poor ability at transducing the airway epithelia,
so this approach was tested using a recombinant adeno-
associated virus (AAV) delivery system [43]. Functional
activity reached approximately 14% of that observed in non-
CF epithelia, similar to the adenoviral vector studies. With
low immunogenicity and the ability to infect multiple tissue
types, recombinant AAV makes an attractive vector for gene
therapy. Additionally, the potential limitation in AAV vector
packaging capacity is less of an issue with SMaRT trans-
splicing, as only a portion of the CFTR cDNA needs to be
delivered.
The majority of trans-splicing studies to date have focused
on restoration of function through replacement of the
portion of the mRNA transcript containing the disease-
causing mutation. However, trans-splicing also has potential
application in treating disorders linked to aberrant splicing.
To investigate regulation of alternative splicing of human
MAPT exon 10, a PTM carrying exons 10–13 of the MAPT
coding region was designed to bind to MAPT intron 9 [44].
Following cotransfection into human neuroblastoma cells
with a tau mini-gene containing exons 9–11, the increase in
the ratio of exon 10 inclusion to exclusion indicated
approximately 34% efﬁciency of trans-splicing [44]. These
results demonstrate that SMaRT can be used to manipulate
alternative splicing and could have therapeutic application
for those disorders that are a consequence of aberrant
splicing.
SMaRT has several advantages over conventional gene
therapy. As the gene is repaired rather than introduced, the
spatial and temporal expression of the gene should be
controlled by endogenous regulation such that protein
expression resembles that for normal individuals. As repair
will only occur where the target transcript is expressed,
adverse effects would not be anticipated in cells that were
nonspeciﬁcally targeted during delivery. Trans-splicing can
also address autosomal dominant disorders. As the level of
repaired transcripts increases, the level of mutant transcript
would be expected to decrease, which gene replacement does
not address. Another advantage is that because only a
fragment of the gene needs to be replaced, the PTM
constructs are easily accommodated in current vector
systems. One of the major disadvantages is that a single PTM,
in most cases, would not be able to address all mutations in an
affected population. There is also the potential for
nonspeciﬁc trans-splicing [45]; however, improvements in
PTM design, especially with regard to the binding domain,
have increased their speciﬁcity [46]. While cotransfection of
mini-gene targets and PTMs have obtained reasonable levels
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expressed pre-mRNA in vivo, splicing efﬁciency is lower [40].
Further optimisation of PTM design will be necessary for high
trans-splicing efﬁciency and, as with all RNA therapeutic
approaches, development of efﬁcient methods of delivery to
the cells where repair is required is essential before this
approach could be considered clinically applicable.
Ribozyme-mediated trans-splicing. Derived from the
naturally occurring Group I self-splicing introns, trans-
splicing ribozymes consist of a guide sequence
complementary to the target sequence, the ribozyme domain,
and a 39 terminal exon that is to be trans-spliced. Following
binding, the ribozyme catalyses trans-splicing between the 39
exons of the ribozyme and the 59 target mRNA (Figure 2B).
Ribozyme-mediated repair was ﬁrst demonstrated for b-
globin mRNA in erythroid precursors from individuals with
sickle cell disease [47]. In myotonic dystrophy, the most
common neuromuscular disease in adults, increased levels of
trinucleotide repeat expansion in the 39 untranslated region
of the dystrophia myotonica-protein kinase (DMPK) gene, are
responsible for the clinical condition [48]. To demonstrate
the feasibility of addressing expansion repeat mutations using
trans-splicing ribozymes, a speciﬁcally designed ribozyme was
used to reduce the number of repeats from 12 to ﬁve, at the 39
end of DMPK transcripts in mammalian cells [49]. This
methodology could be applied to the repair of other repeat
expansion mutations; however, the relatively low efﬁciency
means that it is not yet suitable for clinical application.
Ribozyme-mediated trans-splicing has also been applied in
other disease models in vitro, including p53 and p16
mutations in human ovarian cancer [50] and pancreatic
cancer cell lines [51], respectively. In these studies, ribozymes
were developed to be capable of repairing any mutations in
the coding region of the gene. Although efﬁciencies were low,
as many of these mutations exert a dominant-negative effect,
each trans-spliced mRNA molecule would reduce expression
of the mutant protein while simultaneously increasing wild-
type protein expression.
As well as correcting disease-causing mutations, trans-
splicing ribozymes have the potential to create chimeric gene
transcripts by splicing foreign cDNA to a targeted mRNA.
This was recently demonstrated in targeting cancer cells that
express carcinoembryonic antigen (CEA) for destruction [52].
CEA is a cell surface glycoprotein that is overexpressed in the
doi:10.1371/journal.pgen.0030109.g002
Figure 2. RNA Trans-Splicing
(A) Correction of CF mutations in the CFTR gene using SMaRT. A PTM containing a binding domain (BD), splicing domain (black line), and a coding
domain (orange) incorporating exons 10–24 of wild-type CFTR mRNA, binds to intron 9 of CFTR pre-mRNA (green) containing disease-causing mutations
(stars). SMaRT removes the mutant pre-mRNA such that reprogrammed transcript containing wild-type mRNA allows synthesis of a functional protein.
(B) Ribozyme-mediated trans-splicing for application to trinucleotide repeat expansions. Large (50–2,000) CUG repeat expansion in the 39 untranslated
region of the DMPK gene cause myotonic dystrophy. Ribozymes containing a reduced number of CUG repeats are targeted to the mutant DMPK
transcript (green) via complementary binding mediated by a guide sequence (black bars). Binding of the ribozyme facilitates cleavage of the DMPK
mRNA and trans-splicing of the coding region (orange) and smaller CTG repeat expansion to produce a non-toxic DMPK mRNA transcript.
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neoplasia [53]. Design of a ribozyme that speciﬁcally targeted
CEA mRNA induced a 70%–90% reduction in transcript
levels. Additionally, incorporation of the suicide herpes
simplex thymidine kinase gene into the CEA-targeting
ribozyme promoted mediated highly efﬁcient and speciﬁc
destruction of CEA expressing cancer cells following addition
of the prodrug ganciclovir [52]. Whilst these studies have
demonstrated a proof of principle for ribozyme-mediated
trans-splicing in vitro, it has yet to be used successfully in vivo.
Ribozymes are generally inefﬁcient under physiological
conditions because of their requirement for high Mg
2þ,
although ribozyme modiﬁcations have improved their
efﬁciency in mammalian cells [54]. Also, as these ribozymes
are ;400 nucleotides in length and the therapeutic 39 exon
sequences can be signiﬁcantly larger, expression cassettes will
be a necessity to deliver ribozymes in vivo, which in turn has
all of the associated delivery issues.
RNA Interference: Silencing of Specific mRNA
Isoforms and Mutant Alleles
RNA interference (RNAi) is a highly conserved cellular
mechanism of post-transcriptional gene silencing. Since its
elucidation in 1998 [55], a more detailed understanding of its
biochemical mechanism has revealed that the key effector
molecules of RNAi are double-stranded small interfering
RNAs (siRNAs) of approximately 21 nt in length [56]. These
siRNAs can be artiﬁcially synthesised and delivered
exogenously and also can arise endogenously via the
transcription and processing of microRNA (miRNA) genes
[57]. Depending upon their origin and the degree of sequence
complementarity between siRNA and target mRNA,
outcomes may vary between cleavage of the target mRNA and
translational inhibition. In certain circumstances, siRNAs can
direct the methylation of genomic DNA, thereby contributing
to transcriptional silencing [58]. The intrinsic functions of
RNAi, in particular those of miRNAs, are now known to be
far-reaching, and to be fundamental for basic cellular
processes during development, in differentiated tissues, and
also in disease [59,60]. Exogenous activation of the RNAi
pathway utilising synthetic siRNAs or siRNAs expressed from
plasmid or viral vectors has become invaluable for gene
knockdown in functional genomics and has signiﬁcant
therapeutic potential.
The power and promise of RNAi as a therapeutic modality
lies in its intrinsic cellular mechanism and exquisite sequence
speciﬁcity. In mechanistic terms, RNAi allows very different
therapeutic options from conventional gene therapy. Aside
from the knockdown of genes whose activity is implicated in
disease pathogenesis, for example, in HIV [61], hepatitis B
virus (HBV) [62], macular degeneration [63], Alzheimer
disease [64], and cancer [65], the sequence speciﬁcity of RNAi
allows the targeted knockdown of speciﬁc alternatively
spliced isoforms and mutant disease alleles.
Isoform-speciﬁc RNAi. As many as 74% of all multi-exon
human genes are thought to generate alternatively spliced
transcripts [66]. This enhances proteome diversity; however,
defects in this process are linked to numerous genetic
diseases and cancer. Isoform-speciﬁc RNAi can be engineered
with relative ease by targeting unique sequences within or at
the boundaries of speciﬁc alternatively spliced exons (Figure
3A). This allows the speciﬁc knockdown of foetal, adult,
tissue-speciﬁc, or disease-associated isoforms [67,68]; for
example, the targeting of disease-associated isoforms in
cancer. Five alternatively spliced VEGF isoforms exist, one of
which, VEGF165, is strongly implicated in tumour
angiogenesis. Silencing the VEGF165 isoform with RNAi by
targeting unique sequences at the exons 5–7 boundary is not
only feasible but leaves other functional VEGF isoforms
intact [69]. Another example demonstrates the precision of
RNAi to knockdown speciﬁc protein isoforms from among a
large array of related isoforms with essential cellular
functions. PI3-kinase, a critical signal transducer, comprises
doi:10.1371/journal.pgen.0030109.g003
Figure 3. RNAi for Isoform- and Allele-Specific Silencing
(A) Isoform-specific RNAi to target disease-associated isoforms in cancer.
VEGF165 isoform overexpression is implicated in tumour angiogenesis.
Targeting of the VEGF transcript with siRNA targeted to the exon 5/7
boundaries, in association with RISC, induces specific VEGF165
knockdown, while having no effect on other VEGF isoforms, e.g.,
VEGF189.
(B) Allele-specific RNAi in the autosomal dominant slow channel
congenital myasthenic syndrome. A missense mutation (red bar) in the
muscle acetylcholine a-subunit (aS226F) induces a CﬁU change in the
mutant allele. Use of siRNA specific for the aS226F mutation (A binding
to U), induces discriminatory silencing of the mutant transcript, leaving
the wild-type transcript mostly unaffected.
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Ia PI3-kinase catalytic alpha subunit, is implicated in tumour
angiogenesis. Speciﬁc targeting of this isoform with RNAi has
been demonstrated in a model of ovarian cancer [70].
In cases where aberrant splicing is associated with disease,
isoform-speciﬁc knockdown by RNAi could be exploited to
restore the balance between different isoforms or to target
speciﬁc splicing regulators. Just as trans-splicing PTMs can be
engineered to address the tau isoform imbalance in patients
with frontotemporal dementia with parkinsonism linked to
Chromosome 17, RNAi could be used to reprogram this
balance by reducing the levels of exon 10þ splice variants.
The recent identiﬁcation of tau exon 10 splicing silencers,
such as SRP54 [71], and enhancers [72,73] offers a different
possibility for restoring normal tau splicing by directly
targeting modulators of exon 10 splicing by RNAi. However,
given that splicing is a tightly controlled process, down-
regulation of endogenous splicing factors has the potential to
signiﬁcantly disrupt or alter splicing in nontargeted genes
and off-target effects would need to be carefully monitored.
Allele-speciﬁc RNAi. The exquisite speciﬁcity of RNAi also
opens the possibility of targeting mutant alleles associated
with dominant genetic disease, i.e., where the mutant allele is
pathogenic in the presence of a normal allele [74–76] (see
Figure 3B). This approach permits discrimination between
wild-type and mutant alleles, leaving the former largely
intact, an important consideration given that in many cases
these are essential genes. Critical to this is the capacity of the
RNAi machinery to discriminate single nucleotide
mismatches among closely related gene targets [77]. Original
approaches placed mismatches around central positions 10
and 11 in the siRNA duplex corresponding to nucleotides in
the target mRNA cleaved by the EIF2C2 (previously known as
Ago2) component of the RNA-induced silencing complex
(RISC)[78,79]. It is now appreciated that both the location
and type of nucleotide mismatch inﬂuence allele-speciﬁc
discrimination. Du et al. reported signiﬁcant tolerance for
mismatches at positions 1–4 and 12–19, i.e., mismatches at
these positions offer poor discrimination [80]. Schwarz et al.
conﬁrmed some of these ﬁndings, reporting that mismatches
in the 59 ‘‘seed’’ region (i.e., positions 2–7) are weakly selective
but that mismatches at other positions, notably centrally and
also at position 16, are powerfully discriminative [81]. Thus,
there is a need for further studies to establish to what extent
general rules exist, and also to extend these ﬁndings to
expressed siRNA sequences.
Allele-speciﬁc silencing of several mutant allele targets has
been studied for diseases including osteogenesis imperfecta
[82], sickle cell anaemia [83], primary retinal degeneration
[84], and spinocerebellar ataxia [85]. By designing both
siRNAs and shRNAs with the AChR aS226F mismatch
mutation placed at position 10 in the duplex, signiﬁcant
discrimination between mutant and wild-type knockdown
was demonstrated, as determined at the protein level by
sensitive radio-labelling and other measures [86]. Studies by
several groups have targeted the G85R and G93A mutations
in the Cu/Zn superoxide dismutase (SOD1) gene. Mismatches
either located centrally at position 10 [87], or more 39 [88],
provide good discrimination in vitro. The feasibility of
extending this in vivo has been demonstrated by silencing a
human SOD1 G93A transgene in mice using lentiviral
expression, although these experiments did not show allele-
speciﬁc silencing [89,90]. In another example, a GAG deletion
in the TOR1A gene causes dominantly inherited dystonia.
Placement of a trinucleotide GAG mutation at or near the
centre of the siRNA duplex induces selective silencing of the
mutant gene in vitro in Cos-7 cells expressing both wild-type
and mutant TOR1A [91]. Thus, point mutations and small
deletions appear amenable to an allele-speciﬁc strategy. For
larger mutations, including those of the polyglutamine
diseases, where extended CAG repeats are the common
feature, an alternative approach targeting a SNP linked to the
mutation seems promising. Targeting of a GﬁC SNP
immediately 39 to the CAG repeat in the MJD1 disease allele
that causes spinocerebellar ataxia type 3, shows effective
discrimination between silencing of the wild-type and mutant
alleles [92]. The effectiveness of this approach ultimately
depends on tight linkage between the target SNP and disease
allele; in this particular case, over 70% of disease alleles are
linked to the C variant [92]. There is strong evidence to
indicate that silencing the mutant allele in the most common
polyglutamine disease, Huntington disease, is likely to be
feasible in vivo and of therapeutic value [93–95]. However, as
yet, there are no reports of allele-speciﬁc discrimination
between mutant and wild-type huntingtin. Continued
optimisation of targeting constructs, mismatch positions, and
further identiﬁcation of disease linked SNPs, especially in the
case of Huntington disease, will facilitate progress in this
area.
RNAi limitations. While RNAi offers novel therapeutic
applications and can obviate some of the short-comings of
conventional gene therapy, it is not without its own
limitations. Delivery is a major obstacle to the clinical
exploitation of RNAi therapies. The delivery of synthetic
siRNAs requires improvement via chemical stabilisation and
the development of targeting methods, but in many respects
these molecules can be treated and optimised as conventional
pharmaceutical agents. In contrast, virally expressed siRNAs
retain the advantages but also many of the limitations of
standard gene therapy vector delivery systems. In recent
years, a growing understanding of RNAi biology has allowed
improved siRNA sequence selection and also the
incorporation of nucleotide modiﬁcations to facilitate guide-
strand loading into RISC [96,97]. Nevertheless, nonspeciﬁc
off-target effects, whether due to limited sequence
homologies or to miRNA-like effects, continue to be of
signiﬁcant concern [98]. In the case of siRNAs, it is now
thought that speciﬁc chemical modiﬁcations might abolish or
limit these effects [99,100]. For expressed siRNAs, vector
capacity is not the limiting factor that it can be for
conventional gene therapy; however, the regulatory elements
in these vectors require improvement. Most studies currently
utilise Pol III promoters, commonly U6 or H1, to drive siRNA
expression, but these lack the possibilities for spatial or
temporal regulation. Increasingly, the use of miRNA-like
siRNAs will permit the evaluation of Pol II promoters to drive
tissue-speciﬁc regulation [101]. Finally, while expressed
siRNAs are likely to elicit similar immunological responses
directed against vector components to those reported in
standard gene therapy studies, synthetic siRNAs have their
own set of inﬂammatory concerns. A number of studies have
reported siRNA-induced interferon responses, originally
thought to be associated with longer dsRNAs [102–104]. It is
now known that speciﬁc nucleotide motifs in dsRNAs can
PLoS Genetics | www.plosgenetics.org June 2007 | Volume 3 | Issue 6 | e109 0851activate the immune system via Toll-like receptors (TLRs),
speciﬁcally TLR3, TLR7, TLR8, and TLR9 [105,106]. Where
characterised, such motifs can be avoided in siRNA design
but it is also now known that chemical modiﬁcation at
speciﬁc nucleotides can abolish TLR recognition and
enhance safety [107].
Delivery
The major obstacle to the successful application of all
RNA-based therapies is delivery to target tissues, a problem
further complicated by the potential for rapid degradation by
cellular nucleases. Chemically stabilised forms of antisense
oligonucleotides, e.g., morpholino oligomers and peptide
nucleic acids, and siRNAs, have been developed in efforts to
prolong half-lives and enhance bioavailability. However, for
most applications, re-administration will remain a necessity.
Given the challenges that face nucleic acid delivery, it is likely
that applications involving local rather than systemic delivery
will be the ﬁrst to be evaluated for success in clinical
application. For the majority of nucleic acid chemistries,
complexation or covalent linkage to specialised delivery
agents will be necessary to facilitate cellular uptake. Lipid-
based delivery agents have been combined with chemically
modiﬁed siRNAs to successfully target HBV in a mouse model
of HBV replication [62], and further advances in the lipid-
based agents are being developed by many groups [108]. The
use of nucleic acids directly conjugated to targeting ligands is
another promising approach to enhance delivery. For
example, conjugation of cholesterol to the 39 end of the sense
strand of siRNAs targeting apolipoprotein allows efﬁcient
liver delivery and effective silencing in vivo [109]. More
recently, lipid targeting complexes incorporating
apolipoprotein A-I targeting ligands have proved highly
effective for single, low dose siRNA delivery to liver and
effective gene silencing in an HBV model [110]. Advances in
nanoparticle technology should eventually lead to intelligent
delivery systems that contain stabilised nucleic acid cargoes
within polymer complexes incorporating speciﬁc targeting
ligands [111]. Finally, in some cases, the use of viral
expression systems will be possible and appropriate
depending on the application. For example, the expression of
U7 small nuclear RNA–based constructs using AAV vectors
has proved highly successful for exon skipping in a mouse
model of DMD [36], and a number of siRNA expression
systems using short hairpin RNA- or microRNA-based
constructs have been successfully delivered using AAV [85],
lentivirus [112], and other vector systems. However, viral
delivery of RNA therapeutics will share the same challenges
of more conventional gene replacement therapies, including
immune response to viral vectors.
Conclusion
RNA directed therapy offers a range of specialised
applications not available to conventional gene therapy.
However, promising as such applications appear, their
efﬁcacy has yet to be convincingly demonstrated in clinical
trials, and their success is currently limited by a number of
factors (Box 1). In the absence of expression systems,
oligonucleotide therapies are unlikely to offer permanent
correction and will therefore require re-administration. The
use of more stable nucleic acid chemistries should allow a
reduction in the frequency of dosing, but the long-term
consequences of such re-administration protocols are not yet
known. Another signiﬁcant limitation of most RNA targeting
applications involving oligonucleotides are nonspeciﬁc off-
target effects. While the lengths of such nucleic acids are
generally sufﬁcient to confer target recognition speciﬁcity,
the incorporation or targeting of common nucleotide motifs
(e.g., TLR recognition sites, miRNA binding sites, and ESEs)
means that there is a potential for nonspeciﬁc events. Having
said this, and despite such limitations, progress in the ﬁeld of
RNA therapeutics over the last decade has been remarkable.
A large number of antisense oligonucleotide agents are in
clinical development, including those for specialised
applications such as exon skipping and splicing modiﬁcation.
Phase I and II clinical trials for exon skipping in DMD are
underway in The Netherlands and will start shortly in the
United Kingdom. Therapeutic RNAi developments are not
far behind, with local delivery applications, e.g., Sirna-027
treatment of neovascularization associated with age-related
macular degeneration (http://www.clinicaltrials.gov), the ﬁrst
to be underway. The realisation of the potential of RNA
targeted therapies to address genetic disease suggests that this
ﬁeld has a very promising future. “
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